Key points from article :
Athersys is making significant progress in its research on cell therapy for hemorrhagic trauma, nearing the final stages of patient enrolment in the MATRICS-1 trial. The study, a phase 2 clinical trial, is evaluating invimestrocel (MultiStem)—a stem cell therapy designed to address complications following severe trauma. This therapy, which modulates the immune system to reduce inflammation and promote tissue repair, is being tested on patients who have survived initial treatment for traumatic injuries and are admitted to intensive care.
The trial’s third and final cohort will enrol around 140 participants and utilize MultiStem doses manufactured through a novel 3D bioreactor process, ensuring higher scalability and consistency. This method was first introduced during the second cohort. MultiStem’s unique mechanism of action aims to prevent secondary tissue damage by dampening inflammatory responses soon after injury, which could improve survival and recovery outcomes.
In parallel, Athersys is advancing its research on MultiStem for other conditions, such as ischemic stroke, through its phase 3 MASTERS-2 trial. Recent FDA-approved protocol changes for this stroke trial, including extended monitoring periods and flexibility in patient treatment options, underscore the evolving understanding of MultiStem’s therapeutic potential. These advancements reflect insights from prior trials and collaborations, enhancing the prospects of this innovative therapy for broader clinical use.
Athersys’ work highlights the promise of regenerative medicine in addressing critical and life-threatening conditions, bringing new hope to trauma and stroke patients worldwide.
